Effects of new 17α-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo

British Journal of Cancer

Volumn 81, Issue 4, 1999, Pages 622-630

  Grigoryev, D N ^a   Long, B J ^a   Nnane, I P ^a   Njar, V C O ^a   Liu, Y ^a   Brodie, A M H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

17 hydroxylase C17,20 lyase inhibitors; Androgens synthesis; Azolyl steroids; LNCaP cells; SCID mice

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; AZOLYL STEROID; CYTOCHROME P450; FLUTAMIDE; KETOCONAZOLE; LYASE; LYASE INHIBITOR; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE; UNCLASSIFIED DRUG; VN 107 1; VN 108 1; VN 109 1; VN 63 1; VN 85 1; VN 87 1; ENZYME INHIBITOR; METRIBOLONE; PROSTATE SPECIFIC ANTIGEN; STEROID;

ANDROGEN SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT; ANIMAL; BLOOD; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOUSE MUTANT; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; CELL DIVISION; ENZYME INHIBITORS; HUMANS; MALE; METRIBOLONE; MICE; MICE, SCID; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; STEROIDS; TUMOR CELLS, CULTURED;

EID: 0032589949     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690739     Document Type: Article

References (29)

1. Berns EMJJ, de Boer W and Mulder E (1993) Androgen-dependent growth regulation of and release of specific proteins by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 23: 213-223
2. Chung B, Picado-Leonard J, Hahju M, Bienkowski M, Hall PF, Shively JE and Miller WL (1987) Proc Natl Acad Sci USA 84: 407-411
3. Crawford ED, Eisenberg M, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumstein BA, Davis MA and Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424
4. Crawford ED, Eisenberg M and McLeod DG (1992) Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, prognostic significance of minimal disease, J Urol 147: 417A
5. De Launoit Y, Veilleux R, Dufour M, Simard J and Labrie F (1991) Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 51: 5165-5170
6. Denis I, (1994) Role of maximal androgen blockage in advanced prostate cancer. Prostate 5 (Suppl): 17-22
7. Gormley GJ (1991) Role of 5α-reductase inhibitors in the treatment of advanced prostatic carcinoma. Urol Clin North Am 18: 93-97
8. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas ED, Taylor A, Binkowitz B and Ng J (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992 327: 1185-1191.
9. 17,20-lyase inhibitors. Analyt Biochem 267: 319-330
10. Horoszewicz JS, Lying SS, Kawinski E, Karr IP, Rosental H, Chu TM, Mirand EA and Murphy GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818
11. Jubilerer SJ and Hogan T (1989) High dose ketoconazole for the treatment of hormone-refractory metastatic prostate cancer: 16 cases and review of the literature. J Urol 142: 89-91
12. Klus GT, Nakamura J, Li J-s, Ling Y-z, Son C, Kemppainen JA, Wilson EM and Brodie AMH (1996). Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Cancer Res 56: 4956-4964
13. 17α). J Med Chem 40: 3297-3304
14. 21, steroid side chain cleavage: spectral and binding studies. J Biol Chem 256: 6134-6139
15. 17α): potential agents fur the treatment of prostate cancer. J Med Chem 41: 902-912
16. Pousette A, Carlstrom K, Henriksson P, Grande M and Stege R (1997) Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research. Prostate 31: 198-203
17. Sartor, O, Cooper M, Weinberger M, Headlee D, Thibault A, Tomkins A, Steinberg S, Figg WD, Linehan WM and Myers CE (1994) Surprising activity of flutamide withdrawal, when combined with aminoglutethimide in treatment of hormone-refractory' prostate cancer. J Natl Cancer Inst 86: 222-227
18. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E and Sullivan LD (1997) A metastatic and androgen-sensitive human prostate cancer model using intraprostatic modulation of LNCaP cells in SCID mice. Cancer Res 57: 1584-1589
19. Schuurmans AL, Bolt J, Veldscholte J and Mulder E (1991) Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J Steroid Biochem Mol Biol 40: 193-197
20. Shihata A, Ma J and Whittemore AS (1998) Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 90, 1230-1231
21. Small FJ, Baron A and Bok R (1997) Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80: 1755-1759
22. Trachtenberg J and Pont A (1984) Ketoconazole therapy for advanced prostatic cancer. Lancet 2: 433-435
23. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, Van Rooij HCJ, Trapman J, Brinkmann AO and Mulder E (1990) A mutation in the ligand-binding domain of the androgen receptor of human LNCaP cells affects steroidal binding characteristics and response to androgens. Biochem Biophys Res Comman 173: 534-540
24. Veldscholte J, Berrevoets C, Brinkmann AO, Grootegoed JA and Mulder E (1992) Androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat shock protein interaction and transcription activation. Biochem 31: 2393-2399
25. Visakorpy T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotic A, Tammela T, Isola J and Kallioniemi O-P (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406
26. Webber MM, Bello D and Quader S (1997) Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristic and applications Part 2. Tumorigenic cell lines. Prostate 30: 58-64
27. Wilding C, Chen M and Gellman EP (1989) Aberrant response in vitro of hormone responsive prostate cancer cells to antiandrogens. Prostate 14: 103-115
28. Williams G, Kerle DJ, Doble A, Dunlop H, Smith C, Allen J, Yeo T and Bloom SR (1986) Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol 58: 45-51
29. Wong T, Kelce WR, Sar M and Wilson EM (1995) Androgen receptor antagonist versus agonist activities of the fungicide vinclozin relative to hydroxyflutamide. J Biol Chem 270: 19998-20003